Table 1 Baseline characteristics of study subjects (n = 65)
Characteristic | Number (%) or median (IQR) |
|---|---|
Demographics | |
Age (years) (mean, SD) | 60 (14) |
Male sex | 46 (70.8%) |
Body mass index (kg/m2) (mean, SD) | 22.2 (3.1) |
Comorbidities | |
Diabetes mellitus | 8 (12.3%) |
Liver cirrhosis | 5 (7.7%) |
Chronic kidney disease | 0 (0.0%) |
Solid organ transplant | 8 (12.3%) |
Solid cancer | 29 (44.6%) |
Hematologic cancer | 28 (43.1%) |
Immunocompromised | 1 (1.5%) |
Charlson comorbidity index | 5 (3, 7) |
Source of bacteremia | |
Intraabdominal infection | 33 (50.8%) |
Urinary tract infection | 4 (6.2%) |
Primary bacteremia | 23 (35.4%) |
Others | 5 (7.7%) |
Severity of infection | |
Pitt bacteremia score | 0 (0, 2) |
ICU admission at the onset of bacteremia (n = 63*) | 2 (3.1%) |
Acute kidney injury at the onset of bacteremia | 8 (12.3%) |
Laboratory test at the onset of bacteremia | |
White blood cell count (× 103/μL) | 5.83 (0.28, 12.03) |
Neutropenia | 21 (32.3%) |
C-reactive protein (mg/dL) (n = 64**) | 8.9 (5.4, 12.9) |
CLCr (mL/min) | 96.7 (59.8, 123.9) |
Microbiologic test results | |
Enterococcus faecium isolated | 62 (95.4%) |
Vancomycin MIC determined by broth microdilution (μg/mL) | 1 (1, 1) |
Factors related to vancomycin treatment | |
Initiation of vancomycin as empiric antibiotic | 62 (95.4%) |
Use of loading dose | 14 (21.4%) |
Average AUC24 during initial 72 h (mg/L) | 555 (443, 621) |
Average AUC24/MIC during initial 72 h | 579 (453, 676) |
Average trough concentration (μg/mL) (mean, SD) | 13.71 (4.48) |
Duration of treatment (days) | 10 (7, 13) |
Other factors potentially related to prognosis | |
Bloodstream infection with other microorganism(s) within a month | 27 (41.5%) |
Source control indicated | 26 (40.0%) |
Source control performed (n = 26) | 12 (18.5%) |
Infectious diseases consultation | 45 (69.2%) |